Traditional nonsteroidal anti-inflammatory drugs and postmenopausal hormone therapy: A drug-drug interaction?

PLoS Medicine

Volumn 4, Issue 5, 2007, Pages 0822-0827

  García Rodríguez, Luis Alberto ^a   Egan, Karine ^b   FitzGerald, Garret A ^b  

^a Department of Pharmacoepidemiology   (Spain)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; ACEMETACIN; ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; AZAPROPAZONE; DICLOFENAC; DIFLUNISAL; ESTRADIOL; ESTROGEN; ETODOLAC; FENBUFEN; FENOPROFEN; FLURBIPROFEN; HORMONE; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SULINDAC; TENOXICAM; TIAPROFENIC ACID; TIBOLONE; UNINDEXED DRUG;

ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG MEGADOSE; EPIDEMIOLOGICAL DATA; FEMALE; HEART INFARCTION; HEART PROTECTION; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; AGED; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY DISEASE; DATA BASE; DRUG INTERACTION; ESTROGEN THERAPY; FOLLOW UP; MIDDLE AGED; MORTALITY; RISK; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; CORONARY DISEASE; DATABASES AS TOPIC; DRUG INTERACTIONS; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; POSTMENOPAUSE;

EID: 34249656925     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0040157     Document Type: Article

References (24)

1. Mendelsohn M (2002) Protective effects of estrogen on the cardiovascular system. Am J Cardiol 89: 12E-17E.
2. Rosano GM, Vitale C, Silvestri A, Fini M (2003) Hormone replacement therapy and cardioprotection: The end of the tale? Ann N Y Acad Sci 997: 351-357.
3. Egan K, Lawson J, Fries S, Koller B, Rader D, et al. (2004) COX-2 derived prostacyclin confers atheroprotection on female mice. Science 306: 1954-1957.
4. McAdam BF, Mardini IA, Habib A, Burke A, Lawson JA, et al. (2000) Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J Clin Invest 105: 1473-1482.
5. Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, et al. (2004) Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109: 1468-1471.
6. García Rodríguez LA, Pérez Gutthann S (1998) Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol 45: 419-425.
7. García Rodríguez LA, Varas-Lorenzo C, Maguire A, Gonzá lez-Pérez A (2004) Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 109: 3000-3006.
8. Gillum RF, Fortmann SP, Prineas RJ, Kottke TE (1984) International diagnostic criteria for acute myocardial infarction and acute stroke. Am Heart J 108: 150-158.
9. World Health Organization [WHO] (1976) Myocardial infarction community registers: Results of a WHO international collaborative study coordinated by the Regional Office for Europe. Copenhagen: World Health Organization, Regional Office for Europe. Public Health in Europe, Report Number 5. 232 p.
10. Ridker PM, Cook NR, Lee IM, Gordon D, Graziano JM, et al. (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352: 1293-1304.
11. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, et al. (1988) Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 296: 313-316.
12. Steering Committee of the Physicians' Health Study Research Group (1989) Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321: 129-135.
13. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86. Erratum in BMJ (2002) 324: 141.
14. Shah SH, Alexander KP (2003) Hormone replacement therapy for primary and secondary prevention of heart disease. Curr Treat Options Cardiovasc Med 5: 25-33.
15. Prentice RL, Pettinger M, Anderson GL (2005) Statistical issues arising in the women's health initiative. Biometrics 61: 899-911.
16. Garbe E, Suissa S (2004) Hormone replacement therapy and acute coronary outcomes: Methodological issues between randomized and observational studies. Hum Reprod 19: 8-13.
17. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA 288: 321-333.
18. Gonzá lez-Pérez A, García Rodríguez LA (2005) Breast cancer risk among users of antidepressant medications. Epidemiology 16: 101-105.
19. Mendelsohn ME, Karas RH (2005) Molecular and cellular basis of cardiovascular gender differences. Science 308: 1583-1587.
20. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, et al. (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297: 1465-1477
21. Wassmann K, Wassmann S, Nickenig G (2005) Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function. Circ Res 97: 1046-1054.
22. FitzGerald GA (2004) Coxibs and cardiovascular disease. N Engl J Med 351: 1709-1711.
23. Grosser T, Fries S, FitzGerald GA (2005) Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 116: 4-15.
24. Hsia J, Manson JE, Kuller L, Pettinger M, Choe JH, et al. (2006) Impact of cyclooxygenase inhibitors in the women's health initiative hormone trials: Secondary analysis of a randomized trial. PLoS Clin Trials 1: e26. doi:10.1371/journal.pctr.0010026